We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc (TDOC) Rises Higher Than Market: Key Facts
Read MoreHide Full Article
In the latest close session, Teladoc (TDOC - Free Report) was up +2.33% at $7.02. This move outpaced the S&P 500's daily gain of 0.94%. On the other hand, the Dow registered a gain of 0.75%, and the technology-centric Nasdaq increased by 1.52%.
The telehealth services provider's stock has dropped by 8.78% in the past month, falling short of the Medical sector's gain of 4.95% and the S&P 500's gain of 1.67%.
The upcoming earnings release of Teladoc will be of great interest to investors. It is anticipated that the company will report an EPS of -$0.24, marking a 14.29% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $621.69 million, reflecting a 3.23% fall from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$1.17 per share and a revenue of $2.52 billion, representing changes of +80.07% and -2.12%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Teladoc. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 5.93% higher. Teladoc is holding a Zacks Rank of #3 (Hold) right now.
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 67, positioning it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teladoc (TDOC) Rises Higher Than Market: Key Facts
In the latest close session, Teladoc (TDOC - Free Report) was up +2.33% at $7.02. This move outpaced the S&P 500's daily gain of 0.94%. On the other hand, the Dow registered a gain of 0.75%, and the technology-centric Nasdaq increased by 1.52%.
The telehealth services provider's stock has dropped by 8.78% in the past month, falling short of the Medical sector's gain of 4.95% and the S&P 500's gain of 1.67%.
The upcoming earnings release of Teladoc will be of great interest to investors. It is anticipated that the company will report an EPS of -$0.24, marking a 14.29% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $621.69 million, reflecting a 3.23% fall from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$1.17 per share and a revenue of $2.52 billion, representing changes of +80.07% and -2.12%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Teladoc. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 5.93% higher. Teladoc is holding a Zacks Rank of #3 (Hold) right now.
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 67, positioning it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.